Matinas BioPharma Holdings MTNB
NYSE MTNB
$0.20 +0.02 (+8.93%)
At close: Aug 21, 2026 · 4:00 PM EDT

Matinas BioPharma Holdings (MTNB) Total Debt (2015)

Matinas BioPharma Holdings (MTNB) posted quarterly Total Debt of $843674.0 for Q2 2015, little changed quarter-over-quarter from $843674.0 in Q1 2015.

Matinas BioPharma Holdings (MTNB) Total Debt (2015) Analysis & Trends

Matinas BioPharma Holdings (MTNB) has reported Total Debt for 1 consecutive years, with $843674.0 the latest figure, recorded in Q2 2015.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 591.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 1.07 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 770.36 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 546.77 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 9.34 Bn
10 Matinas BioPharma Holdings 1.25 Mn 437,566.66 - -

Historic Data

Download Data
DateValue
Jun 30, 2015 843,674.00
Mar 31, 2015 843,674.00